Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
Search
Ukraine Help: We fly, we bike, we accommodate
The solidarity for Ukraine from Boehringer Ingelheim employees is incredible. Equally impressive is their practical help.
Research ruminant animal health well-being
Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research
World Water Day: Good Health Hinges on Good Water
Clean, safe and accessible water is the most basic prerequisite for life and health
World Recycling Day: Closing the Loop
Transitioning the economy from a linear to a circular approach herculean task – but also an innovation that carries huge potential
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
1990-2023: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2023, with milestones
Stem cell therapy for tendon and ligament injuries in horses
A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.
Collaboration Boehringer Ingelheim Veeva technology
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
New spesolimab data show significant improvement in GPP flares
New spesolimab data show significant improvement in GPP flares
Big hearts united to help animals in Ukraine
Veterinaries volunteer at the Polish-Ukrainian border to help welcome Refugees and their animals. Refugees don’t rest until their animals are safe.
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Equestrian sports horse health awareness Alex Hua Tian
Together with Olympian trailblazer and eventer Alex Hua Tian, we educate about equine health in China.
FRONTLINE® becomes Brand of the Year 2021-22
FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
New Therapeutic Antibody Discovery Collaboration
Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
How to create an Ariba standard account processing a purchas
Email routing configuration in SAP Ariba accounts
How to configure the Ariba account
Knowing the enemy: PRRS and PCVD
The swine industry is constantly vigilant of viruses such as PRRS and PCV2 (PCVD). Learn about prevention, symptoms knowledge, and control measures to make a difference.
meat consumption market trends growth sustainability
In this article, we’re taking a look at global developments while highlighting one of the most important meat markets of the future: the Asian continent.
Monoclonal antibodies Boehringer Ingelheim and Invetx
Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
2021 PRRS Research Award winners announced
The 2021 European PRRS Research Award winners announced
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.